Vor Biopharma Inc. (VOR) News

Vor Biopharma Inc. (VOR): $4.81

-0.16 (-3.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VOR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter VOR News Items

VOR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VOR News Highlights

  • For VOR, its 30 day story count is now at 5.
  • Over the past 1 day, the trend for VOR's stories per day has been choppy and unclear. It has oscillated between 2 and 3.

Latest VOR News From Around the Web

Below are the latest news stories about Vor Biopharma Inc that investors may wish to consider to help them evaluate VOR as an investment opportunity.

Vor Biopharma Inc.’s (VOR) Stock Is Harder To Predict Than You Think

Vor Biopharma Inc. (NASDAQ:VOR) price on Friday, February 11, fall -7.03% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.60. A look at the stock’s price movement, the close in the last trading session was $9.25, moving within a range at $8.35 and $9.65. Turning to its … Vor Biopharma Inc.’s (VOR) Stock Is Harder To Predict Than You Think Read More »

Stocks Register | February 12, 2022

Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.

GlobeNewswire | February 11, 2022

Vor to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences: H.C. Wainwright BioConnect 2022 Virtual Conference Presentation Date: Monday, January 10, 2022Time: Pre-recorded on-demand presentation available beginning at 7:00 AM ET 2022 B Riley Virtual Oncology ConferenceFireside Chat Live Webcast D

Yahoo | January 4, 2022

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $40.44

Vor Biopharma Inc. (NYSE:VOR) has earned an average rating of Buy from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective []

Transcript Daily | December 19, 2021

Vor Biopharma (NYSE:VOR) Downgraded to Hold at Zacks Investment Research

Vor Biopharma (NYSE:VOR) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. []

Dakota Financial News | December 18, 2021

H.C. Wainwright Initiates a Buy Rating on Vor Biopharma (VOR)

H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage with a Buy rating on Vor Biopharma (VOR – Research Report) today and set a price target of $26.00. The company's shares closed last Thursday at $12.13, close to its 52-week low of $10.48. According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 17.0% and a 44.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Janux Therapeutics Inc, and Cellectar Biosciences. Vor Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $38.80, a 204.8% upside from current levels. In a report issued on December 2, Robert W.

Brian Anderson on TipRanks | December 17, 2021

Vor Biopharma granted FDAs orphan drug designation for leukemia drug

No summary available.

Seeking Alpha | December 17, 2021

Parametric Portfolio Associates LLC Makes New $1.60 Million Investment in Vor Biopharma Inc. (NYSE:VOR)

Parametric Portfolio Associates LLC bought a new position in Vor Biopharma Inc. (NYSE:VOR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 85,631 shares of the companys stock, valued at approximately $1,597,000. Parametric Portfolio Associates LLC owned about 0.23% of Vor Biopharma as of its most []

Transcript Daily | December 15, 2021

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors

CAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Daniella Beckman to its board of directors. Ms. Beckman, who is currently the Chief Financial Officer of Tango Therapeutics and board member for Vor Biopharma

PR Newswire | December 9, 2021

Vor Biopharma a buy at Oppenheimer on engineered stem cells; sees 165% upside

No summary available.

Seeking Alpha | December 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6323 seconds.